Navigation Links
ERT Reports First Quarter 2011 Operating Results
Date:5/2/2011

PHILADELPHIA, May 2, 2011 /PRNewswire/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERT) a global technology-driven provider of  services and customizable medical devices to biopharmaceutical and healthcare organizations and the market leader for centralized cardiac safety and respiratory efficacy services in drug development, announced today results for the first quarter ended March 31, 2011.  Unless otherwise noted, all comparative numbers refer to changes from the same period a year ago.  The financial results include the results related to CareFusion Research Services (RS) commencing from its date of acquisition on May 28, 2010.

This press release contains financial measures prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and non-GAAP measures adjusted to exclude the impact of the amortization of the acquired intangibles and other assets and acquisition and other costs related to the RS acquisition and related income tax effects.  A reconciliation of these GAAP and non-GAAP measures is found in the attached "Reconciliation of GAAP to Non-GAAP Information."

Financial Highlights for the First Quarter of 2011

  • Net revenues were $41.7 million for the first quarter of 2011 compared to $44.9 million for the fourth quarter of 2010 and $21.9 million a year ago.  Revenues from RS were $18.9 million in the first quarter of 2011, compared to $20.0 million in the fourth quarter of 2010.

  • GAAP gross margin percentage was 44.2% in the first quarter of 2011 compared to 43.9% for the fourth quarter of 2010 and 53.8% a year ago.  Non-GAAP gross margin percentage was 48.7% in the first quarter of 2011 compared to 49.0% for the fourth quarter of 2010 and 53.8% a year ago.  

  • GAAP operating income margin percentage was 12.8% in the first quart
    '/>"/>

  • SOURCE ERT
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    2. Spherix Reports Second Quarter Earnings
    3. Tapestry Reports Second Quarter 2007 Results
    4. Callisto Reports on Second-Quarter 2007 Milestones
    5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    9. Biopure Reports on Meeting with the FDA
    10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
    11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... -- Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... that it is appealing the judgment of the Regional Court ... that found the headgear of certain mask models ... invalidity challenges against various ResMed patents in major countries. Apex ... junk patents. ResMed filed the lawsuit with ...
    (Date:7/29/2014)... 29, 2014  Ambit Biosciences (Nasdaq: AMBI ), ... drugs targeting unmet needs in oncology, autoimmune and inflammatory ... results after closing of the NASDAQ Global Market on ... call hosted by Michael Martino , president and ... place on the same day at 5:00 pm EDT ...
    (Date:7/29/2014)... , July 29, 2014  The BioFusionary ... on developing a proprietary electromagnetic induction platform with ... into an agreement under which TBC will merge ... Limited (COT) in an all-stock transaction. ... initially trade on the Australian Stock Exchange under ...
    Breaking Medicine Technology:Apex Continues Fighting Against Patents to Free Up Competition 2Ambit Biosciences To Announce Second Quarter 2014 Financial Results 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3
    ... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
    ... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
    Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
    (Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
    (Date:7/29/2014)... 29, 2014 “Our years of ... homeowners fail to insulate their homes properly simply ... of preventing heat transfer and conduction,” Clean Crawls ... they’ve recently released an article explaining exactly how ... their energy bills. , To contact Clean Crawls ...
    (Date:7/29/2014)... “Approximately 18% of our population suffers from allergies, ... Western Washington Medical Group says in their recently ... from allergies to seek medical attention. , “Billions of ... in the United States,” they continue. “Many people have ... themselves, rather than seeking the appropriate treatment.” , Fortunately, ...
    (Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign ... absorb embarrassing odors in the office. PoofPad is a discrete ... a desk drawer. This compact packaging is designed for ease ... on the pad and poof away! , “We’ve all been ... someone appears out of nowhere. It’s embarrassing and unpleasant for ...
    (Date:7/29/2014)... 29, 2014 Riverdale Urgent Care is ... do. Through their presence at local events, partnerships and ... more than just a medical service for the Riverdale ... money in support of Riverdale RiverFest and South Riverdale ... that features local musicians and entertainers, arts and crafts, ...
    Breaking Medicine News(10 mins):Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3
    ... Regions Hospital,this week opens a new 16-bed inpatient ... the region -- with an innovative way of caring ... schedule,providing improved continuity and a better experience for patients., ... provide care for,patients once they arrive in the emergency ...
    ... Late-Stage and Marketed ... ... England, February 18 /PRNewswire/,-- EUSA Pharma Inc (,EUSA,), a transatlantic ... today,announced that it has out-licensed the exclusive world-wide rights to ...
    ... Cancer Society study of twelve types of cancer among ... were significantly more likely to present with advanced stage ... which appears in the March issue of The Lancet ... investigate insurance status and stage of diagnosis for a ...
    ... known to impair the cognitive health of people, but ... learning and memory problems. A new National Institutes ... increased levels of a stress hormone produced by the ... the region of the brain responsible for learning and ...
    ... District Hospital, Dar es Salaam, Tanzania, WASHINGTON, Feb. ... President, First Lady, my dear wife -- Mr.,President, welcome again ... you so much, again, for PEPFAR, the President,s,Emergency Plan for ... -- these two buildings, a,facility we just visited, and again, ...
    ... Wing, professor of psychiatry and human behavior at The Warren ... Weight Control & Diabetes Research Center at The Miriam Hospital, ... dieters who lose weight and keep the pounds off, have ... , Using new research findings, Wing will make her case ...
    Cached Medicine News:Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 3Health News:Major study links insurance status to advanced stage in multiple cancers 2Health News:Stress hormone impacts memory, learning in diabetic rodents 2Health News:Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar 2Health News:Large changes needed to address global obesity epidemic 2
    1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
    Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
    Penicillin-Streptomycin-Glutamine (100X) liquid...
    Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
    Medicine Products: